Open Access. Powered by Scholars. Published by Universities.®
Translational Medical Research Commons™
Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Allergens (1)
- Animals (1)
- Anti-Anxiety Agents (1)
- Asthma (1)
- Benzodiazepines (1)
-
- Bronchial Hyperreactivity (1)
- Bronchoconstriction (1)
- Cytokines (1)
- Female (1)
- G-Protein-Coupled (1)
- Humans (1)
- Idiopathic Interstitial Pneumonias (1)
- Idiopathic Pulmonary Fibrosis (1)
- Idiopathic interstitial pneumonias (1)
- Idiopathic pulmonary fibrosis (1)
- Immunoglobulins (1)
- Immunoglobulins, Intravenous (1)
- Inbred C57BL (1)
- Intravenous (1)
- Knockout (1)
- Lorazepam (1)
- Male (1)
- Mice (1)
- Mice, Inbred C57BL (1)
- Mice, Knockout (1)
- Phenotype (1)
- Plasma Exchange (1)
- Plasma exchange (1)
- Pneumonia (1)
- Pyroglyphidae (1)
Articles 1 - 2 of 2
Full-Text Articles in Translational Medical Research
Design Of The Strive-Ipf Trial-Study Of Therapeutic Plasma Exchange, Rituximab, And Intravenous Immunoglobulin For Acute Exacerbations Of Idiopathic Pulmonary Fibrosis, Tejaswini Kulkarni, Gerard Criner, Daniel Kass, Ivan Rosas, Mary Beth Scholand, Daniel Dilling, Ross Summer, Steven Duncan
Design Of The Strive-Ipf Trial-Study Of Therapeutic Plasma Exchange, Rituximab, And Intravenous Immunoglobulin For Acute Exacerbations Of Idiopathic Pulmonary Fibrosis, Tejaswini Kulkarni, Gerard Criner, Daniel Kass, Ivan Rosas, Mary Beth Scholand, Daniel Dilling, Ross Summer, Steven Duncan
Division of Pulmonary and Critical Care Medicine Faculty Papers
BACKGROUND: Acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF) affect a significant proportion of patients with IPF. There are limited data to inform therapeutic strategies for AE-IPF, despite its high mortality. We discuss the rationale and design of STRIVE-IPF, a randomized, multi-center, open-label Phase IIb clinical trial to determine the efficacy of combined therapeutic plasma exchange (TPE), rituximab, and intravenous immunoglobulin (IVIG), in comparison to treatment as usual (TAU), among patients with acute IPF exacerbations.
METHODS: The STRIVE-IPF trial will randomize 51 patients among five sites in the United States. The inclusion criteria have been designed to select a study population …
Ogr1-Dependent Regulation Of The Allergen-Induced Asthma Phenotype, Ajay P Nayak, Deepak A. Deshpande, Phd, Sushrut D. Shah, Dominic R Villalba, Roslyn Yi, Nadan Wang, Raymond B. Penn
Ogr1-Dependent Regulation Of The Allergen-Induced Asthma Phenotype, Ajay P Nayak, Deepak A. Deshpande, Phd, Sushrut D. Shah, Dominic R Villalba, Roslyn Yi, Nadan Wang, Raymond B. Penn
Division of Pulmonary and Critical Care Medicine Faculty Papers
The proton-sensing receptor, ovarian cancer G protein-coupled receptor (OGR1), has been shown to be expressed in airway smooth muscle (ASM) cells and is capable of promoting ASM contraction in response to decreased extracellular pH. OGR1 knockout (OGR1KO) mice are reported to be resistant to the asthma features induced by inhaled allergen. We recently described certain benzodiazepines as OGR1 activators capable of mediating both procontractile and prorelaxant signaling in ASM cells. Here we assess the effect of treatment with the benzodiazepines lorazepam or sulazepam on the asthma phenotype in wild-type (WT) and OGR1KO mice subjected to inhaled house dust mite (HDM; …